SCHEMBL2017809

SCHEMBL2017809

COc1ccc(C2C(C)C(=O)N2c2cc(OC)c(OC)c(OC)c2)c(O[Si](C)(C)C(C)(C)C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.41
ESR2 Q92731 2/20 0.41
CA2 P00918 2/20 0.39
CA1 P00915 1/20 0.39
CA4 P22748 1/20 0.39
CA7 P43166 1/20 0.39
HSD11B1 P28845 1/20 0.36
TSHR P16473 2/20 0.36
TP53 P04637 1/20 0.36
MDM2 Q00987 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
TUBB4A P04350 2/20 0.35
TUBB P07437 2/20 0.35
TUBA3C P0DPH7 2/20 0.35
TUBA1B P68363 2/20 0.35
TUBA4A P68366 2/20 0.35
TUBB4B P68371 2/20 0.35
TUBB3 Q13509 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2017807 0.82 ESR1 (0.43) ESR1ESR2CA2CA1CA4
SCHEMBL20707998 0.76 HIF1A (0.45) CA2CA1CA4CA7KDM4E
SCHEMBL2002265 0.76 ESR1 (0.60) ESR1ESR2CA2CA1CA4
SCHEMBL1996385 0.71 NPSR1 (0.53) ESR1ESR2CA2CA1CA4
SCHEMBL13640332 0.68 CA12 (0.59) CA2CA1CA7L3MBTL1ALDH1A1
SCHEMBL29501039 0.68 ESR1 (0.41) ESR1ESR2CA2CA1CA4
SCHEMBL29501085 0.67 ESR1 (0.40) ESR1ESR2CA2CA1CA4
SCHEMBL1997707 0.67 HTR7 (0.42) ESR1ESR2TSHRALDH1A1TUBB4A
SCHEMBL22773180 0.67 P2RX3 (0.38) L3MBTL1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL20708068 0.67 HSD11B1 (0.55) HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120309734-A1 COMBRETASTATIN DERIVATIVES AND USES THEREFOR THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) 2012-12-06 US disclosed
EP-2513051-A1 COMBRETASTATIN DERIVATIVES AND USES THEREFOR The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin (IE) 2012-10-24 EP disclosed
WO-2011073211-A1 COMBRETASTATIN DERIVATIVES AND USES THEREFOR THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309734-A1 COMBRETASTATIN DERIVATIVES AND USES THEREFOR CASP4, CA4, ACSL4 ESR1 3303/4885ESR2 4101/4885CA2 92/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.